Raymond James raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $82 from $77 and keeps a Strong Buy rating on the shares. The company reported another “beat-and-raise” quarter with broad increases in net sales across the Livmarli and bile acid product lines, the analyst tells investors in a research note. The firm remains bullish on Mirum’s outlook.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals price target raised to $81 from $79 at Citizens JMP
- Mirum Pharmaceuticals price target raised to $80 from $73 at H.C. Wainwright
- Strong Commercial Performance and Strategic Initiatives Drive Buy Rating for Mirum Pharmaceuticals
- Mirum Pharmaceuticals Reports Strong Q2 2025 Growth
- Mirum Pharmaceuticals reports Q2 EPS (12c), consensus (33c)